{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:51:07Z","timestamp":1782478267441,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00120-026-02842-3","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:05:59Z","timestamp":1779177959000},"page":"737-744","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Indikation der antihormonellen Therapie (ADT) beim fortgeschrittenen Prostatakarzinom beim \u00e4lteren Patienten","Reassessing androgen deprivation therapy (ADT) in older men with advanced prostate cancer: when to use, when to discontinue, and role as monotherapy?"],"prefix":"10.1007","volume":"65","author":[{"given":"Martina","family":"Heller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Zsch\u00e4bitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,19]]},"reference":[{"issue":"12","key":"2842_CR1","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1002\/cncr.26392","volume":"118","author":"E Scosyrev","year":"2012","unstructured":"Scosyrev\u00a0E et\u00a0al (2012) Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer 118(12):3062\u20133070","journal-title":"Cancer"},{"key":"2842_CR2","volume-title":"Krebs in Deutschland f\u00fcr 2021 \u2013 2023","author":"Berlin., R.K.-I.H.u.D.K.e.V.H.","year":"2025","unstructured":"Berlin., R.K.-I.H.u.D.K.e.V.H. (2025) Krebs in Deutschland f\u00fcr 2021 \u2013 2023"},{"key":"2842_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2019.04.031","volume":"116","author":"HJ Boyle","year":"2019","unstructured":"Boyle\u00a0HJ et\u00a0al (2019) Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. Eur J Cancer 116:116\u2013136","journal-title":"Eur J Cancer"},{"key":"2842_CR4","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390396","volume":"43","author":"LS Graham","year":"2023","unstructured":"Graham\u00a0LS et\u00a0al (2023) Management of Prostate Cancer in Older Adults. Am Soc Clin Oncol Educ Book 43:e390396","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"2842_CR5","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jgo.2020.05.011","volume":"11","author":"IC van Walree","year":"2020","unstructured":"van Walree\u00a0IC et\u00a0al (2020) Clinical judgment versus geriatric assessment for frailty in older patients with cancer. J\u00a0Geriatr Oncol 11(7):1138\u20131144","journal-title":"J Geriatr Oncol"},{"issue":"10","key":"2842_CR6","doi-asserted-by":"publisher","first-page":"7745","DOI":"10.3390\/curroncol29100612","volume":"29","author":"GL Banna","year":"2022","unstructured":"Banna\u00a0GL et\u00a0al (2022) The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network. Curr Oncol 29(10):7745\u20137753","journal-title":"Curr Oncol"},{"issue":"8","key":"2842_CR7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","volume":"23","author":"CA Bellera","year":"2012","unstructured":"Bellera\u00a0CA et\u00a0al (2012) Screening older cancer patients: first evaluation of the G\u20118 geriatric screening tool. Ann Oncol 23(8):2166\u20132172","journal-title":"Ann Oncol"},{"issue":"5","key":"2842_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jgo.2018.03.014","volume":"9","author":"ME Hamaker","year":"2018","unstructured":"Hamaker\u00a0ME et\u00a0al (2018) The effect of a geriatric evaluation on treatment decisions and outcome for older cancer patients - A systematic review. J\u00a0Geriatr Oncol 9(5):430\u2013440","journal-title":"J Geriatr Oncol"},{"issue":"12","key":"2842_CR9","doi-asserted-by":"publisher","first-page":"e949","DOI":"10.1093\/oncolo\/oyac147","volume":"27","author":"P Rescigno","year":"2022","unstructured":"Rescigno\u00a0P et\u00a0al (2022) Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network. Oncologist 27(12):e949\u2013e956","journal-title":"Oncologist"},{"issue":"3","key":"2842_CR10","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1161\/ATVBAHA.119.313046","volume":"40","author":"JR Hu","year":"2020","unstructured":"Hu\u00a0JR et\u00a0al (2020) Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer: Contemporary Meta-Analyses. Arterioscler Thromb Vasc Biol 40(3):e55\u2013e64","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"2842_CR11","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.jaccao.2023.05.011","volume":"5","author":"AJ Nelson","year":"2023","unstructured":"Nelson\u00a0AJ et\u00a0al (2023) Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. JACC CardioOncol 5(5):613\u2013624","journal-title":"JACC CardioOncol"},{"issue":"4","key":"2842_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/jdi.12472","volume":"7","author":"H Wang","year":"2016","unstructured":"Wang\u00a0H et\u00a0al (2016) Androgen deprivation therapy is associated with diabetes: Evidence from meta-analysis. J\u00a0Diabetes Investig 7(4):629\u2013636","journal-title":"J Diabetes Investig"},{"issue":"7","key":"2842_CR13","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.jgo.2023.101594","volume":"14","author":"MB Kova\u010d","year":"2023","unstructured":"Kova\u010d\u00a0MB et\u00a0al (2023) The trajectory of sarcopenia following diagnosis of prostate cancer: A systematic review and meta-analysis. J\u00a0Geriatr Oncol 14(7):101594\u2013101594","journal-title":"J Geriatr Oncol"},{"issue":"6","key":"2842_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pros.24676","volume":"84","author":"SU Qazi","year":"2024","unstructured":"Qazi\u00a0SU et\u00a0al (2024) Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis. Prostate 84(6):525\u2013538","journal-title":"Prostate"},{"key":"2842_CR15","unstructured":"Lipp\u00a0HP et\u00a0al (2025) Androgen receptor-targeted therapies - avoid clinically relevant interactions. Aktuelle Urol."},{"issue":"3","key":"2842_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/bju.16577","volume":"135","author":"AD Raval","year":"2025","unstructured":"Raval\u00a0AD et\u00a0al (2025) Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a\u00a0systematic review. BJU Int 135(3):408\u2013421","journal-title":"BJU Int"},{"issue":"11","key":"2842_CR17","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1080\/14796694.2025.2481024","volume":"21","author":"PJ Goebell","year":"2025","unstructured":"Goebell\u00a0PJ, Chen\u00a0S, Jhaveri\u00a0J (2025) Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK. Future Oncol 21(11):1377\u20131390","journal-title":"Future Oncol"},{"issue":"6","key":"2842_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102171","volume":"22","author":"CN Sternberg","year":"2024","unstructured":"Sternberg\u00a0CN et\u00a0al (2024) Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale. Clin Genitourin Cancer 22(6):102171","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"2842_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102410","volume":"23","author":"L Dottorini","year":"2025","unstructured":"Dottorini\u00a0L et\u00a0al (2025) Reassessing the Evidence: Is Intensified Therapy Justified in Older Patients with Metastatic Hormone-Sensitive Prostate Cancer? Clin Genitourin Cancer 23(5):102410","journal-title":"Clin Genitourin Cancer"},{"issue":"4","key":"2842_CR20","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.euo.2023.11.012","volume":"7","author":"F Gomez-Veiga","year":"2024","unstructured":"Gomez-Veiga\u00a0F et\u00a0al (2024) Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged \u3008\u202f75 and \u2265\u202f75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol 7(4):860\u2013869","journal-title":"Eur Urol Oncol"},{"key":"2842_CR21","doi-asserted-by":"crossref","unstructured":"Mourey\u00a0L et\u00a0al (2023) Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy \u00b1 docetaxel in older patients (\u2265\u202f70\u00a0years), with de novo metastatic-castration sensitive prostate. J\u00a0Clin Oncol.","DOI":"10.1200\/JCO.2023.41.6_suppl.20"},{"issue":"1","key":"2842_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41416-023-02492-8","volume":"130","author":"J Shen","year":"2024","unstructured":"Shen\u00a0J et\u00a0al (2024) Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. Br J Cancer 130(1):73\u201381","journal-title":"Br J Cancer"},{"key":"2842_CR23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ejca.2021.10.015","volume":"159","author":"U De Giorgi","year":"2021","unstructured":"De Giorgi\u00a0U et\u00a0al (2021) Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. Eur J Cancer 159:237\u2013246","journal-title":"Eur J Cancer"},{"key":"2842_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113258","volume":"192","author":"K Fizazi","year":"2023","unstructured":"Fizazi\u00a0K et\u00a0al (2023) Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Eur J Cancer 192:113258","journal-title":"Eur J Cancer"},{"issue":"11","key":"2842_CR25","volume":"17","author":"Y Tohi","year":"2025","unstructured":"Tohi\u00a0Y et\u00a0al (2025) Real-World Clinical Outcomes of Darolutamide in Older Patients With Non-metastatic Castration-Resistant Prostate Cancer: A Multi-institutional Comparative Analysis of Efficacy and Tolerability. Cureus 17(11):e97911","journal-title":"Cureus"},{"issue":"2","key":"2842_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/annonc\/mdv542","volume":"27","author":"JN Graff","year":"2016","unstructured":"Graff\u00a0JN et\u00a0al (2016) Efficacy and safety of enzalutamide in patients 75\u00a0years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol 27(2):286\u2013294","journal-title":"Ann Oncol"},{"issue":"5","key":"2842_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.eururo.2013.09.005","volume":"65","author":"PF Mulders","year":"2014","unstructured":"Mulders\u00a0PF et\u00a0al (2014) Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 65(5):875\u2013883","journal-title":"Eur Urol"},{"issue":"4","key":"2842_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/bju.16106","volume":"132","author":"T Yanagisawa","year":"2023","unstructured":"Yanagisawa\u00a0T et\u00a0al (2023) Impact of performance status on efficacy of systemic therapy for prostate cancer: a\u00a0meta-analysis. BJU Int 132(4):365\u2013379","journal-title":"BJU Int"},{"issue":"16","key":"2842_CR29","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland\u00a0SJ et\u00a0al (2023) Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer. N\u00a0Engl J Med 389(16):1453\u20131465","journal-title":"N Engl J Med"},{"issue":"6","key":"2842_CR30","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S1470-2045(14)70129-9","volume":"15","author":"B Tombal","year":"2014","unstructured":"Tombal\u00a0B et\u00a0al (2014) Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study. Lancet Oncol 15(6):592\u2013600","journal-title":"Lancet Oncol"},{"issue":"5","key":"2842_CR31","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.euo.2024.01.009","volume":"7","author":"BF Tombal","year":"2024","unstructured":"Tombal\u00a0BF et\u00a0al (2024) A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). Eur Urol Oncol 7(5):1051\u20131060","journal-title":"Eur Urol Oncol"},{"key":"2842_CR32","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","volume":"158","author":"FC Maluf","year":"2021","unstructured":"Maluf\u00a0FC et\u00a0al (2021) A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer 158:63\u201371","journal-title":"Eur J Cancer"},{"issue":"1","key":"2842_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euf.2025.05.006","volume":"12","author":"T Fazekas","year":"2026","unstructured":"Fazekas\u00a0T et\u00a0al (2026) Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life\u2011A Systematic Review and Meta-analysis. Eur Urol Focus 12(1):109\u2013130","journal-title":"Eur Urol Focus"},{"issue":"4","key":"2842_CR34","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/s41391-022-00533-6","volume":"25","author":"CH Ohlmann","year":"2022","unstructured":"Ohlmann\u00a0CH et\u00a0al (2022) LHRH sparing therapy in patients with chemotherapy-na\u00efve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis 25(4):778\u2013784","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"5","key":"2842_CR35","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.eururo.2013.04.020","volume":"64","author":"A Sciarra","year":"2013","unstructured":"Sciarra\u00a0A et\u00a0al (2013) Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 64(5):722\u2013730","journal-title":"Eur Urol"},{"issue":"8","key":"2842_CR36","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41585-020-0335-7","volume":"17","author":"M Perera","year":"2020","unstructured":"Perera\u00a0M et\u00a0al (2020) Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer. Nat Rev Urol 17(8):469\u2013481","journal-title":"Nat Rev Urol"},{"issue":"4","key":"2842_CR37","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","volume":"2","author":"DL Hershman","year":"2016","unstructured":"Hershman\u00a0DL et\u00a0al (2016) Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol 2(4):453\u2013461","journal-title":"JAMA Oncol"},{"issue":"9","key":"2842_CR38","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/jsxmed\/qdaf164","volume":"22","author":"BCG Nascimento","year":"2025","unstructured":"Nascimento\u00a0BCG et\u00a0al (2025) Prospective study of endogenous testosterone recovery following neoadjuvant hormonal blockade and radical prostatectomy in high-risk prostate cancer patients. J\u00a0Sex Med 22(9):1554\u20131563","journal-title":"J Sex Med"},{"issue":"1","key":"2842_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2023-000198","volume":"3","author":"HL Bromley","year":"2024","unstructured":"Bromley\u00a0HL et\u00a0al (2024) Comparison of standard-dose and reduced-dose treatment of metastatic prostate cancer with enzalutamide, apalutamide or darolutamide: a\u00a0rapid review. BMJ Oncol 3(1):e000198","journal-title":"BMJ Oncol"},{"key":"2842_CR40","doi-asserted-by":"crossref","unstructured":"Morgans\u00a0AK et\u00a0al (2026) Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer. Clin Genitourin Cancer. :102536","DOI":"10.1016\/j.clgc.2026.102536"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02842-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-026-02842-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-026-02842-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:36:36Z","timestamp":1782477396000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-026-02842-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,19]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2842"],"URL":"https:\/\/doi.org\/10.1007\/s00120-026-02842-3","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,19]]},"assertion":[{"value":"16 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Heller gibt an, dass kein Interessenkonflikt besteht. S.\u00a0Zsch\u00e4bitz gibt folgende Interessenskonflikte an: Advisory Board\/Honoraria (institutionell und\/oder person\u00f6lich): Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, EISAI, EUSA, Gilead, Ipsen, Johnson&Johnson, Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi Aventis, StreamedUp, Urotrials, Urotube, Zentiva. Research funding (institutionell): Eisai. Clinical trial support (institutional): Amgen, AstraZeneca, AVEO, Bayer, Biontech, Bristol-Myers Squibb, Calithera, Exelixis, Gilead, Lilly, MSD, Novartis, Pfizer, Roche, Seagen\/Astellas, Urotrials, Travels & conferences: Amgen, Astellas, AstraZeneca, Bayer, EISAI, Ipsen, Johnson&Johnson, Merck, MSD, Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}